electroCore (Nasdaq:ECOR) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ECOR 주식 개요

는 미국, 영국 및 전 세계에 비침습적 미주신경 자극 기술 플랫폼을 제공하는 상용 단계의 바이오 전자 의학 및 웰니스 회사입니다.

ECOR 기본 분석
눈송이 점수
가치 평가	5/6
미래 성장	5/6
과거 실적	0/6
재무 상태	6/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 92.6% 에서 거래

수익은 매년 69.46% 증가할 것으로 예상됩니다.

지난 5년 동안 수입이 매년 23.5% 증가했습니다.

동종업계 및 업계 대비 좋은 가치로 거래

위험 분석

지난 1년 동안 주주가 희석되었습니다.

의미 있는 시가총액이 없습니다. ( $37M )

electroCore, Inc. 경쟁사

ReWalk Robotics

NasdaqCM:LFWD

US$36.2m

NeuroOne Medical Technologies

NasdaqCM:NMTC

US$22.7m

Precision Optics Corporation

NasdaqCM:POCI

US$35.1m

Lucid Diagnostics

NasdaqCM:LUCD

US$37.8m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 electroCore
과거 주가
현재 주가	US$6.11
52주 최고치	US$8.08
52주 최저치	US$3.83
베타	0.60
11개월 변경	-10.37%
3개월 변경 사항	-2.40%
1년 변경 사항	51.24%
33년 변화	-76.04%
5년 변화	-77.86%
IPO 이후 변화	-97.95%

최근 뉴스 및 업데이트

Recent updates

electroCore (NASDAQ:ECOR) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Jan 07

electroCore gains on distribution deal for gammaCore Sapphire in Eastern Europe

Dec 22

electroCore shares jump 9% on positive results in migraine prevention study

Dec 08

electroCore (ECOR) Investor Presentation - Slideshow

Nov 20

주주 수익률

	ECOR	US Medical Equipment	US 마켓
7D	-3.6%	0.4%	0.4%
1Y	51.2%	-0.6%	22.9%

수익률 대 산업: ECOR 지난 1년 동안 -0.5 %를 반환한 US Medical Equipment 산업을 초과했습니다.

수익률 대 시장: ECOR 지난 1년 동안 23.3 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is ECOR's price volatile compared to industry and market?
ECOR volatility
ECOR Average Weekly Movement	7.8%
Medical Equipment Industry Average Movement	7.7%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

안정적인 주가: ECOR 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: ECOR 의 주간 변동성( 8% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2005	68	Dan Goldberger	www.electrocore.com

는 미국, 영국 및 국제적으로 비침습적 미주신경 자극 기술 플랫폼을 제공하는 상용 단계의 바이오 전자 의학 및 웰니스 회사입니다. 이 회사는 편두통 및 일과성 군발성 두통과 관련된 통증의 급성 치료와 지속적인 편두통 및 발작성 편두통 치료를 위해 정기적으로 또는 간헐적으로 사용하기 위한 처방 전용 휴대용 기기인 감마코어(GammaCore)를 개발하고 있습니다. 또한 일반적인 건강 및 웰빙 지원을 위한 트루바가(Truvaga)와 운동 능력 향상을 위한 탁스팀(TAC-STIM)도 개발하고 있습니다.

electroCore, Inc. 기본 사항 요약

electroCore 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ECOR 기본 통계
시가총액	US$37.18m
수익(TTM)	-US$16.47m
수익(TTM)	US$18.69m

2.1x

P/S 비율

-2.4x

P/E 비율

ECOR 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ECOR 손익 계산서(TTM)
수익	US$18.69m
수익 비용	US$3.23m
총 이익	US$15.46m
기타 비용	US$31.93m
수익	-US$16.47m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-2.56
총 마진	82.70%
순이익 마진	-88.12%
부채/자본 비율	0%

ECOR 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

ECOR 주식 개요

보상

위험 분석

electroCore, Inc. 경쟁사

NasdaqCM:LFWD

US$36.2m

NasdaqCM:NMTC

US$22.7m

NasdaqCM:POCI

US$35.1m

NasdaqCM:LUCD

US$37.8m

가격 내역 및 성능

최근 뉴스 및 업데이트

electroCore, Inc. has completed a Derivatives Offering in the amount of $1.446525 million.

electroCore, Inc. has announced a Derivatives Offering in the amount of $1.446525 million.

electroCore, Inc. Appoints Donald Melnikoff as SVP, Engineering, Regulatory, and Compliance

electroCore, Inc. to Report Q1, 2024 Results on May 08, 2024

electroCore, Inc. Announces Results of Truvaga Plus Consumer Study

electroCore, Inc. Announces the Launch of Truvaga Plus® for General Wellness

Recent updates

electroCore, Inc. has completed a Derivatives Offering in the amount of $1.446525 million.

electroCore, Inc. has announced a Derivatives Offering in the amount of $1.446525 million.

electroCore, Inc. Appoints Donald Melnikoff as SVP, Engineering, Regulatory, and Compliance

electroCore, Inc. to Report Q1, 2024 Results on May 08, 2024

electroCore, Inc. Announces Results of Truvaga Plus Consumer Study

electroCore, Inc. Announces the Launch of Truvaga Plus® for General Wellness

electroCore, Inc. to Report Q4, 2023 Results on Mar 13, 2024

electroCore, Inc. Appoints Charles S. Theofilos as New Class Iii Member of the Board

Electrocore, Inc. Announces Data Highlighting Non-Invasive Vagus Nerve Stimulation (Nvns) for Treatment of Symptoms of Gastroparesis

electroCore, Inc. to Report Q3, 2023 Results on Nov 08, 2023

electroCore, Inc. Announces the Publication of Two Peer Reviewed Publication of Two Peer Reviewed Publications Supporting the Use of Gammacore ( Non-Invasive Vagus Nerve Stimulation; nVNS) in Patients with Post Traumatic Stress Disorder

electroCore, Inc. Announces Dismissal of All Litigation Related to Its 2018 Initial Public Offering

electroCore, Inc. Reiterates Revenue Guidance for the Year 2023

electroCore, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Electrocore Provides Earnings Guidance for the Second Quarter and Full Fiscal Year 2023

electroCore, Inc., Annual General Meeting, Aug 04, 2023

electroCore, Inc. Reiterates Revenue Guidance for the Year Ending December 31, 2023

electroCore, Inc. Provides Preliminary Earnings Guidance for the Fourth Quarter and Full Year of 2022

electroCore Receives a Determination Letter from Nasdaq Regarding Minimum Bid Price

electroCore, Inc. Launches New Wellness Product Offering for Stress, Anxiety and Sleep, Truvaga

electroCore, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

electroCore, Inc. to Report Q3, 2022 Results on Nov 03, 2022

electroCore, Inc. Provides Revenue Guidance for the Third Quarter of 2022

electroCore sees Q3 revenue below consensus

electroCore is issued 4 new U.S. patents in nVNS therapy

electroCore, Inc., Annual General Meeting, Dec 02, 2022

electroCore, Inc. Announces Publication of a Peer Reviewed Manuscript, Transcutaneous Cervical Vagus Nerve Stimulation Reduces Behavioral and Physiological Manifestations of Withdrawal in Patients with Opioid Use Disorder

electroCore, Inc. Provides Revenue Guidance for the Third Quarter of 2022

electroCore, Inc. to Report Q2, 2022 Results on Aug 04, 2022

electroCore, Inc. Provides Preliminary Unaudited Earnings Guidance for the Second Quarter of 2022

electroCore sees Q2 revenue estimate higher than consensus

Electrocore, Inc. Announces Study of Gammacore Sapphire™ for the Treatment of Post-Covid Syndrome

electroCore Announces Listing Transfer to the Nasdaq Capital Market

Co-Founder recently bought US$56k worth of stock

Electrocore, Inc. Announces Gammacore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers

Electrocore, Inc. Announces Gammacore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

electroCore, Inc. Provides Earnings Guidance for the Second Quarter of 2022

We Think electroCore (NASDAQ:ECOR) Can Afford To Drive Business Growth

High number of new directors

electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in Neurology

electroCore, Inc. Provides Unaudited Preliminary Revenue Guidance for the First Quarter of 2022

High number of new directors

Consensus EPS estimates fall by 11%

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Price target decreased to US$2.80

electroCore, Inc. to Report Q4, 2021 Results on Mar 10, 2022

electroCore, Inc. Announces Completion of Enrollment in the TRANSIT Study of non-Invasive Vagus Nerve Stimulation (nVNS) in Post-Operative Ileus

electroCore, Inc. Provides Revenue Guidance for the Full Year of 2021

electroCore, Inc. Announces Publication of Premium II Trial of Gammacore (Non-Invasive Vagus Nerve Stimulation; nVNS) for the Prevention of Migraine

electroCore: Pioneering Bioelectronic Medicine

Third quarter 2021 earnings released: US$0.057 loss per share (vs US$0.10 loss in 3Q 2020)

electroCore Announces 510(k) Clearance of gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) to Treat Paroxysmal Hemicrania and Hemicrania Continua

Second quarter 2021 earnings released: US$0.06 loss per share (vs US$0.13 loss in 2Q 2020)

Consensus forecasts updated

electroCore, Inc. Announces Revenue Guidance for the Second Quarter of 2021

electroCore, Inc. has completed a Follow-on Equity Offering in the amount of $18 million.

electroCore completes sale of $1.4M of NOL tax benefits

electroCore, Inc. Announces Publication of Study on Non-Invasive Vagus Nerve Stimulation (nVNS) to Improve Clinical Outcomes and Molecular Biomarkers in Parkinson’S Disease Patients